Register to attend a free NIH webinar featuring a licensing opportunity for a first-of-its-kind male contraceptive hormonal gel, Nestorone®/Testosterone (NES/T), co-developed by the NICHD and Population Council through the Contraceptive Clinical Trials Network (CCTN). This topical, daily self-applied transdermal gel is designed to provide full sperm suppression within 8-12 weeks and be reversible after 12-16 weeks of ending application. This presentation will showcase NES/T gel as an innovative, user-controlled option for male contraception.

About the Featured Technology

This novel technology was developed through a partnership of the NICHD and the Population Council, operating through the CCTN, that is dedicated to the co-development of male contraceptives. A partner is being actively sought to license and advance this product, currently in Phase IIb evaluation with interim data available, through the final stage of clinical testing, regulatory approval, and commercial launch. This novel NES/T male gel is the first hormonal male contraceptive product targeted to reach the market.

Competitive Advantages

• Significant, unmet medical need given few current options for male contraceptives
• Significant, unmet medical need given few current options for male contraceptives
• High observed efficacy
• Low rate of observed side effects
• Reversible (return to fertility)
• High level of acceptability
• Based on FDA approved compound (Nestorone® aka segesterone acetate) combined with transdermal testosterone (FDA approved) in a novel formulation
• Patent pending

If you are unable to attend this webinar, you can find more information on the Nestorone®, Testosterone Male Contraceptive Gel abstract.